ArticleScientific reports2026
Determinants of cervical cancer screening among women living with HIV in Lesotho using nationally representative 2023/24 DHS data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women living with HIV are more prone to develop cervical cancer since they have a compromised immune system; hence, they need to be screened continuously in an attempt to identify and prevent it. Despite Lesotho's high HIV prevalence (25.6%), cervical cancer screening coverage and its determinants among women living with HIV remain insufficiently characterized. This study aimed to quantify the rate and determinants of cervical cancer screening among women living with HIV using the 2023/24 Lesotho DHS data. Cross-sectional analysis was performed using the Lesotho DHS Individual Women's Recode file. A weighted sample of 611 HIV-positive women aged 25 years and older participated in the study, as this age group is eligible for cervical cancer screening. Individual and community-level factors were determined using multilevel mixed-effects logistic regression. The level of significance was determined by the 95% confidence interval and a p value less than 0.05 for associations. The total prevalence of cervical cancer screening among women living with HIV was 85.4%. Women aged 40-44 years (adjusted odds ratio [AOR] 4.14; 95% confidence interval [CI] 1.53-11.18) and those who had a clinical breast exam (AOR 5.53; 95% CI 2.54-12.05) were more likely to undergo cervical cancer screening, whereas low parity (AOR 0.19; 95% CI 0.05-0.78) and rural residence (AOR 0.50; 95% CI 0.25-0.99) were associated with lower odds of screening. Adoption of cervical cancer screening among women living with HIV in Lesotho is high, with most screened women receiving normal results. Screening uptake varied by demographics, being higher among older women and those who had breast examinations, while lower among women with low parity and rural residents. Integration of breast and cervical cancer screening, rural outreach targeting, and health education for low-parity women can increase coverage and equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.